Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 5/20 | 0.74 |
| ▸ | CTSK | P43235 | 5/20 | 0.74 |
| ▸ | CTSS | P25774 | 4/20 | 0.74 |
| ▸ | CTSC | P53634 | 3/20 | 0.74 |
| ▸ | CTSL | P07711 | 3/20 | 0.74 |
| ▸ | USP30 | Q70CQ3 | 14/20 | 0.73 |
| ▸ | UCHL1 | P09936 | 13/20 | 0.73 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3814037 | 1.00 | CTSB (0.74) | CTSBCTSKCTSSCTSCCTSL | |
| SCHEMBL3808642 | 0.85 | CTSK (1.00) | CTSBCTSKCTSSCTSCCTSL | |
| SCHEMBL3813897 | 0.85 | CTSB (0.74) | CTSBCTSKCTSSCTSCCTSL | |
| SCHEMBL3818016 | 0.85 | CTSB (0.74) | CTSBCTSKCTSSCTSCCTSL | |
| SCHEMBL3811242 | 0.85 | CTSB (0.74) | CTSBCTSKCTSSCTSCCTSL | |
| SCHEMBL3810898 | 0.85 | CTSK (1.00) | CTSBCTSKCTSSCTSCCTSL | |
| SCHEMBL3815699 | 0.85 | CTSB (0.74) | CTSBCTSKCTSSCTSCCTSL | |
| SCHEMBL20576333 | 0.84 | USP30 (1.00) | CTSBCTSKCTSSCTSCCTSL | |
| SCHEMBL6856730 | 0.84 | USP30 (1.00) | CTSBCTSKCTSSCTSCCTSL | |
| SCHEMBL13644758 | 0.84 | USP30 (1.00) | CTSBCTSKCTSSCTSCCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009129371-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | claimed |
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | claimed |
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009129371-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20090264499-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264499-A1 | Cathepsin C Inhibitors | CTSB, CTSF, CTSG | CTSB 1/4885CTSK 8/4885CTSS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.